INTERVIEW
How does the company enable Indian pharma companies to meet international biosimilarity and regulatory standards?
Agilent is actively supporting Indian pharmaceutical companies through a combination of advanced technology, specialized training, and strategic partnerships to help them meet global biosimilarity and regulatory standards.
It offers a comprehensive suite of compliance support services, including Instrument qualification( IQ / OQ / PQ), Computer system validation( CSV), and OpenLab CDS software with builtin data integrity and audit trail features. These tools are aligned with international regulatory frameworks, ensuring that Indian labs can maintain data integrity, traceability, and audit readiness. Beyond technology, Agilent invests in capacity building through its India Solution Center, offering hands-on training, regulatory workshops, and method development support tailored to the needs of Indian pharma. These programs are designed to upskill local scientists and quality teams in areas like analytical method validation, biosimilarity characterization, and compliance documentation.
Agilent also collaborates with industry stakeholders to co-develop customized workflows for biosimilar development, helping Indian manufacturers accelerate time-to-market while maintaining global quality benchmarks.
What support does Agilent’ s India Solution Center in Manesar offer including lab training, method development, and customized workflows?
The India Solution Center in Manesar is a 12,500 sq. ft. facility offering endto-end support across chromatography, mass spectrometry, spectroscopy, genomics, and lab informatics. It provides hands-on training, method development, proofof-concept demonstrations, and customized analytical workflows tailored to Indian market needs. The center also aligns with national initiatives like“ Make in India” to foster local innovation and scientific advancement.
Going forward, what market segments are you targeting for your next phase of expansion in India?
Agilent is focusing on high-growth segments such as biopharmaceuticals, clinical diagnostics, food safety, environmental monitoring, and cell and cancer biology. The company’ s strategic investments, including the India Solution Center, are aimed at supporting these sectors with localized, scalable, and sustainable solutions. Agilent also plans to expand its digital and automation offerings to meet the evolving needs of Indian laboratories.
28
BioVoiceNews | July-August 2025